RECEIVES CE MARK FOR FIRST IVD IMMUNOASSAY BLOOD TEST TO IDENTIFY CARRIERS OF APOE4, A GENETIC VARIANT PRESENT IN UP TO 60% OF PATIENTS DIAGNOSED WITH ALZHEIMER'S DISEASE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.